Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959835 | 0.90 | CLPP (0.38) | CLPPGAAALDH1A1LMNAKDM4E | |
| SCHEMBL1959748 | 0.88 | CLPP (0.37) | CLPPGAAALDH1A1LMNAKDM4E | |
| SCHEMBL1962393 | 0.88 | CLPP (0.37) | CLPPGAAALDH1A1LMNAKDM4E | |
| SCHEMBL1962303 | 0.85 | RAB9A (0.44) | CLPPALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL1962289 | 0.84 | NPC1 (0.38) | CLPPGAAALDH1A1LMNAKDM4E | |
| SCHEMBL1960359 | 0.84 | NPC1 (0.35) | CLPPALDH1A1KDM4EGALR3NR2F2 | |
| SCHEMBL1962577 | 0.82 | MAPK13 (0.39) | CLPPGAAALDH1A1LMNAKDM4E | |
| SCHEMBL1959602 | 0.81 | HTR2C (0.39) | GAAKDM4EHTR2CGRIN2BKMT2A | |
| SCHEMBL1959641 | 0.79 | NPC1 (0.40) | CLPPALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL1962298 | 0.79 | CXCR2 (0.37) | CLPPGAAALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332938-B1 | Viral inhibitors | LEUVEN K U RES & DEV (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | CLPP 2023/4885GAA 864/4885ALDH1A1 2022/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | CLPP 1682/4885GAA 79/4885ALDH1A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.